Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.783 USD | -3.20% | -3.08% | -3.33% |
Jun. 05 | HC Wainwright Adjusts Price Target on HOOKIPA Pharma to $6 From $5, Maintains Buy Rating | MT |
Jun. 04 | Transcript : HOOKIPA Pharma Inc. - Special Call |
Financials (USD)
Sales 2024 * | 53.82M | Sales 2025 * | 9.85M | Capitalization | 80.04M |
---|---|---|---|---|---|
Net income 2024 * | -47M | Net income 2025 * | -104M | EV / Sales 2024 * | -0.17 x |
Net cash position 2024 * | 89M | Net cash position 2025 * | - | EV / Sales 2025 * | 8.13 x |
P/E ratio 2024 * |
-2.35
x | P/E ratio 2025 * |
-1.22
x | Employees | 165 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.47% |
Latest transcript on HOOKIPA Pharma Inc.
1 day | -3.20% | ||
1 week | -3.08% | ||
Current month | -1.39% | ||
1 month | +1.95% | ||
3 months | +6.53% | ||
6 months | +18.64% | ||
Current year | -3.33% |
Managers | Title | Age | Since |
---|---|---|---|
Jörn Aldag
CEO | Chief Executive Officer | 65 | 16-05-31 |
Reinhard Kandera
DFI | Director of Finance/CFO | 54 | 17-03-31 |
Klaus Orlinger
CTO | Chief Tech/Sci/R&D Officer | 46 | 12-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jörn Aldag
CEO | Chief Executive Officer | 65 | 16-05-31 |
Chairman | 63 | 17-09-30 | |
Reinhard Kandera
DFI | Director of Finance/CFO | 54 | 17-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 0.783 | -3.20% | 408,674 |
24-06-11 | 0.8089 | +2.13% | 225,321 |
24-06-10 | 0.792 | -3.30% | 386,931 |
24-06-07 | 0.819 | +1.11% | 634,677 |
24-06-06 | 0.81 | +0.26% | 400,392 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.33% | 80.04M | |
+48.79% | 780B | |
+41.76% | 627B | |
+19.43% | 334B | |
+7.18% | 296B | |
+17.60% | 244B | |
-0.41% | 217B | |
+11.54% | 214B | |
+4.53% | 161B | |
-3.92% | 159B |
- Stock Market
- Equities
- HOOK Stock